doi: 10.1136/bmj.f2025.
Hyperplasia from GLP-1 drugs is "not a surprise," say researchers
- PMID: 23535260
- DOI: 10.1136/bmj.f2025
Item in Clipboard
Hyperplasia from GLP-1 drugs is "not a surprise," say researchers
BMJ.
.
No abstract available
Similar articles
-
Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.BMJ. 2013 Jul 10;347:f4386. doi: 10.1136/bmj.f4386. BMJ. 2013. PMID: 23842435 No abstract available.
-
Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation.BMJ. 2013 Jun 11;346:f3782. doi: 10.1136/bmj.f3782. BMJ. 2013. PMID: 23757752 No abstract available.
-
Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?Cleve Clin J Med. 2010 Aug;77(8):503-5. doi: 10.3949/ccjm.77a.09167. Cleve Clin J Med. 2010. PMID: 20682512 No abstract available.
-
[Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].Orv Hetil. 2016 Apr 3;157(14):523-8. doi: 10.1556/650.2016.30409. Orv Hetil. 2016. PMID: 27017851 Review. Hungarian.
-
Incretin therapy and its effect on body weight in patients with diabetes.Prim Care Diabetes. 2012 Oct;6(3):187-91. doi: 10.1016/j.pcd.2012.04.006. Epub 2012 May 19. Prim Care Diabetes. 2012. PMID: 22613745 Review.
Cited by
-
Studying pancreatic risks caused by incretin-based therapies: is it a game? It's not a game!J Diabetes Sci Technol. 2014 Jul;8(4):895-7. doi: 10.1177/1932296814532874. Epub 2014 May 12. J Diabetes Sci Technol. 2014. PMID: 24876434 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
